(Q46798121)

25 December 2017

review article

1 reference

title

Potential therapeutic approaches for prevention and treatment of diabetic nephropathy and neuropathy: evidences of cilostazol (English)

1 reference

25 December 2017

1 reference

Marcelo P Rosa

1

1 reference

25 December 2017

Gislaine V Baroni

series ordinal

2

1 reference

25 December 2017

Vera L Portal

series ordinal

3

1 reference

25 December 2017

language of work or name

Portuguese

0 references

publication date

1 December 2007

1 reference

25 December 2017

Arquivos Brasileiros de Endocrinologia e Metabologia

published in

1 reference

25 December 2017

volume

51

1 reference

25 December 2017

issue

9

1 reference

25 December 2017

page(s)

1528-1532

1 reference

25 December 2017

Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

Cilostazol treatment of claudication in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

Treating peripheral arterial disease in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

The pharmacology of cilostazol

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

Analysis of the cilostazol safety database

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

Comparative effects of cilostazol and other therapies for intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

Current medical therapies for patients with peripheral arterial disease: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

Global and societal implications of the diabetes epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

Hypertension, the endothelial cell, and the vascular complications of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

The natural history of type 2 diabetes. Implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

Endothelial dysfunction in diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

Alterations in EDHF-type relaxation and phosphodiesterase activity in mesenteric arteries from diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

Potential therapeutic approaches to the treatment or prevention of diabetic neuropathy: evidence from experimental studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

New developments in diabetic neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

Cilostazol improves endothelium-derived hyperpolarizing factor-type relaxation in mesenteric arteries from diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

Cilostazol prevents impairment of slow axonal transport in streptozotocin-diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

Cilostazol inhibits high glucose-mediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via NO production

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

Cilostazol, a phosphodiesterase inhibitor, improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty Rat, a model of spontaneous NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

Cilostazol, a phosphodiesterase inhibitor, reduces microalbuminuria in the insulin-resistant Otsuka Long-Evans Tokushima Fatty rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: analysis with quantitative bleeding time and platelet aggregation test

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

Rationale and protocol of a trial for prevention of diabetic atherosclerosis by using antiplatelet drugs: study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000900017

10.1590/S0004-27302007000900017

21 January 2018

Identifiers

DOI

1 reference

25 December 2017

1 reference

25 December 2017